|
04 Apr 2025 |
Syngene Intl
|
Consensus Share Price Target
|
724.65 |
839.50 |
- |
15.85 |
buy
|
|
|
|
|
04 Aug 2016
|
Syngene Intl
|
GEPL Capital
|
724.65
|
458.00
|
412.90
(75.50%)
|
Target met |
Buy
|
|
|
Syngene International ltd. (SIL) Limited is one of India's leading contract research company. SIL is founded in 1993 and a subsidiary of Biocon Ltd. Syngene is a leading custom research and manufacturing organization, which supports R&D; programs from lead generation to clinical supplies. The company's multi-disciplinary skills in integrated drug discovery and development include capabilities in medicinal chemistry, biology, toxicology, custom synthesis, process R&D;, cGMP manufacturing, formulation and analytical development. The company provides significant cost advantage to companies seeking to minimize their R&D; spends. The lower cost structure in Asia Pacific region helps in reducing R&D; spend by...
|
|
25 Jul 2016
|
Syngene Intl
|
ICICI Securities Limited
|
724.65
|
445.00
|
426.10
(70.07%)
|
Pre-Bonus/
Split |
Hold
|
|
|
ICICI Securities Ltd | Retail Equity Research Revenues grew 17.5% YoY to | 274.5 crore (I-direct estimate: | 302.6 crore) mainly due to growth in the discovery services vertical and development and manufacturing group. Adjusting for the impact of sales return, growth would have been 22.5% EBITDA margins declined 120 bps to 32.3% YoY (I-direct estimate: 32.3%) owing to higher employee cost and other expenditure, which was partially offset by improvement in gross margins. EBITDA grew...
|
|
27 Apr 2016
|
Syngene Intl
|
ICICI Securities Limited
|
724.65
|
445.00
|
388.55
(86.50%)
|
Target met |
Buy
|
|
|
ICICI Securities Ltd | Retail Equity Research Revenues grew 31.7% YoY to | 331.5 crore (I-direct estimate: | 316.1 crore) on account of expansion in services for dedicated clients,...
|
|
03 Mar 2016
|
Syngene Intl
|
ICICI Securities Limited
|
724.65
|
445.00
|
392.15
(84.79%)
|
Target met |
Buy
|
|
|
biotechnology, agrochemical, consumer health, animal health, cosmetic and nutrition companies on a fee-based contractual arrangement. SIL provides a gamut of integrated, end-to-end services to develop novel...
|
|
01 Oct 2015
|
Syngene Intl
|
Ashika Research
|
724.65
|
385.00
|
328.90
(120.33%)
|
Target met |
Buy
|
|
|
Syngene International Limited is an internationally reputed contract research and manufacturing organisation with multidisciplinary skills in chemistry and biology services. The...
|
|
20 Jul 2015
|
Syngene Intl
|
Phillip Capital
|
724.65
|
|
|
Pre-Bonus/
Split |
|
|
|
global innovators. Syngene offers integrated discovery and development services to over211 clients globally (103 in CY12) in pharma, biotech, agrochemical and other industries.Longstandingrelationshipswithcustomershasbeenakeystrength.Someofits...
|